肺癌的分子生物学预后因素研究进展(6)
28.Harpole DH,Herndon JE,Young WG.Stage one non-small-cell lung cancer:a multivariate analysis of treatment methods and patterns of recurrence.Cancer,1995,76:787-96
29.Yuen A, Halsey J, Fisher G, et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001;20:1234a
30.Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC.) Proc Am Soc Clin Oncol, 2001;20:1226a
31.]Ciardieno F, Caputo R, Biaoco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053-2063., http://www.100md.com(程超)
29.Yuen A, Halsey J, Fisher G, et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001;20:1234a
30.Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC.) Proc Am Soc Clin Oncol, 2001;20:1226a
31.]Ciardieno F, Caputo R, Biaoco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053-2063., http://www.100md.com(程超)